Latest From Norgine BV
Germany’s OTC Market in 2018: Online Sees Double-Digit Growth, Bionorica’s Canephron Uno Tops New Launches
Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.
Takeda and Norgine’s decision to finally end their alliance for cetilistat in Japan, years after the obesity drug was approved in its first potential market, serves as another sign of the sector’s challenges in the country.
- Diagnostic Imaging Equipment & Supplies
- Specialty Pharmaceuticals
- Therapeutic Areas
- Hepatic (Liver)
- Neurology, Nervous System
- Norgine International Ltd.
- Western Europe
- Company Type
- Midsize European
- Parent & Subsidiaries
- Norgine BV
- Senior Management
Peter Stein, Chmn. & CEO
Christopher Bath, CFO
Paul Pay, Chief Bus. Dev. Officer
Alastair Benbow, Chief Dev. & Medical Officer
Kenneth Scrimgeour, Chief Commercial Officer
- Contact Info
Phone: (31) 1895 826 600
Amsterdam, 1101 CA
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.